Expertise
Quality and safety at the core of our work
With over three decades of biotechnology expertise, we develop therapies with a clear focus on safety, quality, and scientific evidence.
Our expertise
Where our expertise makes a difference
Where our expertise makes a difference
References
-
Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermatoendocrinol. 2012;4(3):253-258.
-
Legré-Boyer V. Viscosupplementation: Techniques, indications, results. Orthop Traumatol Surg Res. 2015;101(1):S101-S108.
-
Flores C, Balius R, Álvarez G, et al. Efficacy and Tolerability of Peritendinous Hyaluronic Acid in Patients with Supraspinatus Tendinopathy: a Multicenter,
-
Yang YJ, Lee WY, Kim Y jin, Hong Y pyo. A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. Int J Environ Res Public Health. 2021;18(5):2383.
-
Pavelka K, Bruyère O, Cooper C, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016;33(2):75-85.
-
Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339-48.
-
Zheng WJ, Tang FL, Li J, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006;21(2):75-80.
-
Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44(11):2539-47.
-
Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury: a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med. 1991;324(26):1829-1838.
-
Aureli M, Mauri L, Ciampa MG, et al. GM1 Ganglioside: Past Studies and Future Potential. Mol Neurobiol. 2016;53(3):1824-1842.
-
Alter M, and the SASS investigators. Ganglioside GM1 in acute ischemic stroke. The SASS trial. Stroke. 1994;25(6):1141-8.
-
Svennerholm L, Brane G, Karlsson I, et al. Alzheimer Disease – Effect of Continuous Intracerebroventricular Treatment with GM1 Ganglioside and a Systematic Activation Programme. Dement Geriatr Cogn Disord. 2002;14(3):128-36.
-
Schneider JS, Roeltgen DP, Mancall EL, et al. Parkinson’s disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology. 1998;50(6):1630-6.